CAR-T CELL THERAPY IN CHINA
HOSPITALS, COST & OUTCOMES

CAR T-Cell therapy in China — Patient Questions

• 1

  1. What is CAR-T cell therapy and how does it work?

  CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of personalized immunotherapy where a patient's own T cells are collected, genetically engineered in a laboratory to express a receptor that recognizes specific proteins on cancer cells, and then infused back into the body to seek and destroy the cancer. The process typically takes three to six weeks from cell collection to infusion. 

  CAR-T therapy is most established for blood cancers, including B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma, where it has produced deep and durable responses in patients who had run out of standard treatment options.

• 2

  2. Is CAR-T cell therapy available in China?

  Yes. China is one of the most active countries in the world for CAR-T therapy, both in terms of approved products and ongoing clinical trials. As of 2024, China's National Medical Products Administration (NMPA) has approved multiple CAR-T products, including Relma-cel (developed by JW Therapeutics) and CT053 (developed by CARsgen Therapeutics). 

  China also hosts an extraordinarily large number of Phase I and Phase II CAR-T trials across a wide range of cancer types, many of which are open to international patients at specialist hematology centers.

• 3

  3. Which CAR-T products are approved in China?

  China has approved several CAR-T products through its NMPA regulatory authority. These include Relma-cel (axicabtagene ciloleucel biosimilar, CD19-targeting, for large B-cell lymphoma), CT053 (a BCMA-targeting product developed by CARsgen for multiple myeloma), and other products from companies such as Legend Biotech, IASO Bio, and Gracell Biotechnologies. 

  Several more products are under regulatory review or in late-stage clinical trials. The number of domestically developed CAR-T products in China is significantly larger than in most other countries, reflecting the scale of investment and research in this area.

• 4

  4. How much does CAR-T therapy cost in China?

  CAR-T therapy in China is considerably more affordable than in the United States or Europe. Approved CAR-T products in China typically cost between USD 70,000 and USD 150,000, compared to USD 400,000 to USD 500,000 in the United States. For international patients accessing CAR-T through clinical trials in China, the therapy itself may be provided at reduced cost or free of charge as part of the trial protocol, though patients are still responsible for hospitalization, supportive care, and travel costs. 

  Total treatment costs including hospital stay, supportive medications, and monitoring generally add between USD 15,000 and USD 40,000 to the base therapy cost, depending on the center and the patient's clinical profile.

• 5

  5. Which hospitals in China offer CAR-T therapy?

  Several leading hospitals in China offer both approved CAR-T products and access to investigational CAR-T programs through clinical trials. These include Fudan University Shanghai Cancer Center (FUSCC), Peking University People's Hospital, Ruijin Hospital (Shanghai Jiao Tong University), the Institute of Hematology and Blood Diseases Hospital (Tianjin), Sun Yat-sen University Cancer Center (Guangzhou), West China Hospital (Chengdu), and Nanfang Hospital (Guangzhou). Each center has specific areas of expertise. Patient eligibility for a given programme depends on the cancer type, prior treatment history, and molecular profile.

• 6

  6. What cancers can be treated with CAR-T therapy in China?

  In China, approved CAR-T products target B-cell malignancies (using CD19-directed constructs) and multiple myeloma (using BCMA-directed constructs). Beyond approved indications, Chinese clinical trials are investigating CAR-T for a wide range of conditions, including T-cell lymphoma, acute myeloid leukemia (AML), follicular lymphoma, and an expanding list of solid tumors, including lung cancer, liver cancer, gastric cancer, and nasopharyngeal carcinoma. 

  Solid tumor CAR-T programs are currently investigational and reflect Phase I and Phase II research, meaning they are not yet standard of care. Patients interested in solid tumor CAR-T should be evaluated for appropriate trials.

• 7

  7. Can international patients access CAR-T therapy in China?

  Yes. Many Chinese hospitals with CAR-T programs accept international patients, and China's clinical trial infrastructure increasingly includes provisions for cross-border enrollment. International patients typically need to submit recent medical reports, pathology results, prior treatment records, and molecular or genetic testing results for pre-screening evaluation. 

  If eligible, the hospital coordinates cell collection, manufacturing, and infusion. A stay of approximately four to eight weeks in China is usually required for the first treatment cycle. CancerFax helps international patients navigate this process, from report review through hospital coordination and travel planning.

• 8

  8. How do I know if I am eligible for CAR-T therapy in China?

  Eligibility for CAR-T therapy depends on several factors: cancer type and subtype, disease stage, the specific antigens expressed on your cancer cells (such as CD19 or BCMA), the number and type of prior treatment lines, organ function, performance status, and whether your disease is active enough to qualify. For approved products, the eligibility criteria generally mirror international standards. 

  For clinical trials, criteria vary by program. A detailed review of your medical reports, pathology, and molecular findings is needed before eligibility can be assessed. CancerFax can help coordinate this pre-screening process with appropriate specialist centers in China.

• 9

  9. What is the process for getting CAR-T therapy in China as a foreign patient?

  The typical process for an international patient accessing CAR-T therapy in China involves the following steps: sharing complete medical records for pre-screening review, receiving an eligibility assessment from the treating center, arranging travel and visa documentation, undergoing a pre-treatment evaluation on arrival, proceeding to T-cell collection (leukapheresis), waiting for cell manufacturing (typically two to four weeks), receiving pre-conditioning chemotherapy, undergoing CAR-T infusion, and staying for post-infusion monitoring and toxicity management. 

  The entire process from arrival to discharge generally takes between four and eight weeks depending on the program and the patient's response. After returning home, follow-up monitoring is coordinated with local physicians.

• 10

  10. What is the difference between approved CAR-T and investigational CAR-T in China?

  Approved CAR-T products in China have completed the full clinical development process and received NMPA authorization for specific indications. They are prescribed by physicians according to approved protocols and are commercially available at authorized centers. Investigational CAR-T refers to products being tested in clinical trials at the Phase I or Phase II stage. 

  These may include novel targets, dual-targeting constructs, allogeneic (off-the-shelf) platforms, or applications in cancer types not yet covered by approved products. Investigational CAR-T may be accessible through trial enrollment and, in some cases, offers earlier access to potentially important therapies, but they carry greater uncertainty about efficacy and safety profiles than approved products.